Over the past 12 months, 5 insiders at Zentalis Pharmaceuticals, Inc. filed 11 open-market SEC Form 4 transactions on ZNTL: 1 purchase worth $7.8M and 10 sales worth $10.1M. Insiders have been net sellers over this period. The most recent filing was on Feb 10, 26.
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| Feb 10, 26 | Vincent VultaggioPAO and PFO | SELL | 6.9K | $2.42 | $17K |
| Feb 9, 26 | Ingmar BrunsChief Medical Officer | SELL | 335 | $2.39 | $801 |
| Feb 9, 26 | Julia Marie EastlandCEO & President | SELL | 889 | $2.39 | $2K |
| Feb 9, 26 | Vincent VultaggioPAO and PFO | SELL | 3.4K | $2.39 | $8K |
| Feb 6, 26 | Ingmar BrunsChief Medical Officer | SELL | 3.0K | $2.43 | $7K |
| Feb 6, 26 | Julia Marie EastlandCEO & President | SELL | 7.9K | $2.43 | $19K |
| Feb 6, 26 | Vincent VultaggioPAO and PFO | SELL | 30.0K | $2.43 | $73K |
| Feb 3, 26 | Vincent VultaggioPAO and PFO | SELL | 556 | $2.52 | $1K |
| Feb 2, 26 | Vincent VultaggioPAO and PFO | SELL | 2.5K | $2.55 | $6K |
| Dec 31, 25 | William Thurman WaltersTenPercentOwner | BUY | 6.46M | $1.20 | $7.8M |
| Dec 15, 25 | David E. GoelTenPercentOwner | SELL | 7.50M | $1.33 | $10.0M |
| Apr 30, 25 | Scott Dunseth MyersDirector | BUY | 21.0K | $1.40 | $29K |
| Feb 6, 25 | Ingmar BrunsChief Medical Officer | BUY | 20.0K | $2.28 | $46K |
| Feb 3, 25 | Mark LacknerChief Scientific Officer | SELL | 14.4K | $1.71 | $25K |
| Feb 3, 25 | Andrea PaulChief Legal Officer | SELL | 13.2K | $1.71 | $23K |
| Feb 3, 25 | Vincent VultaggioPAO and Interim PFO | SELL | 2.6K | $1.71 | $4K |
| Jan 31, 25 | Julia Marie EastlandCEO & President | BUY | 28.5K | $1.73 | $49K |
| Jan 31, 25 | Jan SkvarkaDirector | BUY | 60.0K | $1.72 | $103K |
| Jan 31, 25 | Luke Nathaniel WalkerDirector | BUY | 14.2K | $1.76 | $25K |
| Jan 2, 25 | Mark LacknerChief Scientific Officer | SELL | 4.4K | $3.12 | $14K |
| Oct 4, 24 | Vincent VultaggioPrincipal Accounting Officer | SELL | 1.6K | $3.18 | $5K |
| May 31, 24 | Cam GallagherPresident, Interim CFO | SELL | 9.6K | $11.98 | $115K |
| May 9, 24 | Diana HausmanChief Medical Officer | SELL | 3.4K | $12.62 | $42K |
| Feb 12, 24 | Epperly Melissa BChief Financial Officer | SELL | 2.6K | $11.44 | $29K |
| Feb 12, 24 | Cam GallagherPresident | SELL | 1.2K | $11.44 | $13K |
| Feb 2, 24 | Epperly Melissa BChief Financial Officer | SELL | 8.7K | $11.54 | $100K |
| Feb 2, 24 | Cam GallagherPresident | SELL | 11.6K | $11.54 | $133K |
| Feb 2, 24 | Mark LacknerChief Scientific Officer | SELL | 1.6K | $11.54 | $18K |
| Feb 2, 24 | Andrea PaulChief Legal Officer | SELL | 3.3K | $11.54 | $38K |
| Nov 13, 23 | Kimberly BlackwellChief Executive Officer | BUY | 5.0K | $10.29 | $51K |
| Nov 10, 23 | David Michael JohnsonDirector | BUY | 17.0K | $9.88 | $168K |
| Oct 4, 23 | Carrie BrownsteinChief Medical Officer | SELL | 8.9K | $19.91 | $173K |
| Oct 4, 23 | Kevin D. BunkerChief Scientific Officer | SELL | 5.1K | $19.91 | $99K |
| Oct 4, 23 | Epperly Melissa BChief Financial Officer | SELL | 4.6K | $19.91 | $89K |
| Sep 11, 23 | Jan SkvarkaDirector | SELL | 5.0K | $25.05 | $125K |
| Jun 20, 23 | Matrix Capital Management Company, LpTenPercentOwner | BUY | 4.76M | $22.66 | $107.9M |
| May 31, 23 | Cam GallagherPresident | SELL | 18.5K | $26.40 | $486K |
| May 26, 23 | Kevin D. BunkerChief Scientific Officer | SELL | 80.0K | $30.02 | $2.4M |
| Feb 14, 23 | Kevin D. BunkerChief Scientific Officer | SELL | 6.5K | $19.98 | $130K |
| Feb 14, 23 | Epperly Melissa BChief Financial Officer | SELL | 5.2K | $19.98 | $104K |
| Feb 14, 23 | Cam GallagherPresident | SELL | 8.5K | $19.96 | $170K |
| Feb 13, 23 | Kevin D. BunkerChief Scientific Officer | SELL | 3.8K | $20.42 | $78K |
| Feb 13, 23 | Epperly Melissa BChief Financial Officer | SELL | 2.6K | $20.42 | $54K |
| Feb 13, 23 | Cam GallagherPresident | SELL | 3.3K | $20.42 | $68K |
| Feb 6, 23 | Cam GallagherPresident | SELL | 9.4K | $23.04 | $209K |
| Jan 17, 23 | Cam GallagherPresident | SELL | 9.5K | $24.87 | $229K |
| Jan 5, 23 | Cam GallagherPresident | SELL | 9.7K | $21.46 | $204K |
| Nov 15, 22 | Cam GallagherPresident | SELL | 11.6K | $23.48 | $264K |
| Nov 8, 22 | Cam GallagherPresident | SELL | 12.4K | $23.56 | $292K |
| Nov 7, 22 | Cam GallagherPresident | SELL | 12.3K | $24.24 | $292K |
Over the past 12 months, insiders at Zentalis Pharmaceuticals, Inc. filed 1 open-market purchase worth $7.8M and 10 sales worth $10.1M on ZNTL, which makes them net sellers over the period. The most recent Form 4 was filed on Feb 10, 26.
The largest recent open-market ZNTL insider purchase in our data was $107.9M by Matrix Capital Management Company, Lp, TenPercentOwner, filed on Jun 20, 23.
5 different insiders at Zentalis Pharmaceuticals, Inc. filed open-market SEC Form 4 transactions on ZNTL over the last 12 months.
InsiderTape plots every ZNTL insider buy and sell directly on the price chart and flags new SEC Form 4 filings as they arrive, with cluster detection and buy/sell pressure. The data updates daily from SEC EDGAR.
InsiderTape plots every Zentalis Pharmaceuticals, Inc. insider buy and sell on the price chart, with buy/sell pressure, cluster detection, and alerts the moment new Form 4s hit. Start a free 7-day trial, cancel anytime.
Does it work? In five years of data, insider clusters beat the Russell 2000 about 60% of the time and the CFO's buy was the sharpest signal of all. See the backtest →
START FREE TRIAL →